Sareum Holdings plc

(“Sareum” or “the Company”)

Additional disclosure concerning Michael Owen

Sareum Holdings PLC, the specialist small molecule drug development business, announced on 13 November 2018 the appointment of Michael Owen as a Non-Executive Director of the Company.

It has come to Sareum’s attention that whilst his former directorship of BliNK Biomedical SAS (“BliNK”) was detailed in that announcement, his former directorship of BliNK’s subsidiary Blink Therapeutics Limited during the five years prior to that announcement should also have been included.

 

For further information, please contact: 

Sareum

   
   

Holdings plc

 

Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser)

Chris Fielding / James Sinclair-Ford

020 7220 1666

Hybridan LLP (Nominated Broker)

 

Claire Noyce

020 3764 2341

Citigate Dewe Rogerson (Media enquiries)

 

Shabnam Bashir/ Mark Swallow/ David Dible

020 7638 9571

   
   
  • @Sareumplc Latest tweet

    RT @RobinDavison2: Just checking slide from $BMY's #JPM21 deck on deucravacitinib (TKY2, aka BMS-986165) - very bullish with $4bn+ sales po… via @Sareumplc
    View more